Most Read Articles
Dr. Joseph Delano Fule Robles, 25 Oct 2016

Nivolumab did not meet the primary endpoint of superior progression-free survival (PFS) vs platinum-based chemotherapy in the phase III Checkmate026 trial in patients with stage IV recurrent, PD-L1–positive non-small-cell lung carcinoma (NSCLC), according to results reported recently at the European Society of Medical Oncology (ESMO) Congress 2016. 

Pearl Toh, 24 Nov 2016
New treatments such as pirfenidone and nintedanib slow lung function decline and progression of idiopathic pulmonary fibrosis (IPF), although response to treatment can vary dramatically among patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
16 Oct 2016
Irritable bowel syndrome and asthma share a bidirectional association, a new study reports. Further, atopy potentially plays a role in the underlying mechanisms of this association.
Audrey Abella, 09 May 2018
The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.

3 parameters for cluster change in stable COPD patients

08 May 2018

Cluster assignment has been maintained by most of the patients with chronic obstructive pulmonary disease (COPD) after 2 years of follow-up, according to a study. The principal driving parameters in those who change their cluster assignment include exercise tolerance, lung function and quality of life.

This study evaluated 521 smokers with COPD at baseline and 2 years later. At both evaluation periods, three different clusters were identified consistently: cluster A (of younger age, mild airway limitation, few symptoms), cluster B (intermediate) and cluster C (of older age, severe airway limitation and highly symptomatic).

After 2 years of follow-up, 70 percent of patients remained unchanged, while the rest changed from one cluster to another (20 percent from A to B; 15 percent from B to A; 15 percent B to C; 42 percent from C to B; and 8 percent from C to A).

The main parameters responsible for this cluster shift were 6-minute walking distance (6MWD), forced expiratory volume in 1 s (FEV1) % and COPD Assessment Test (CAT).

The following variables were evaluated in COPD patients at baseline and 2 years later: age, gender, pack-year history, body mass index, modified Medical Research Council scale, 6MWD, spirometry and CAT. Cluster analysis was used to conduct patient classification at baseline and 2 years later.

The investigators also explored each patient’s cluster variability after 2 years and its parameters associated with cluster change.

“Cluster analysis has been utilized to explore phenotypic heterogeneity in COPD,” the investigators said. “To date, little is known about the longitudinal variability of clusters in COPD patients.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 25 Oct 2016

Nivolumab did not meet the primary endpoint of superior progression-free survival (PFS) vs platinum-based chemotherapy in the phase III Checkmate026 trial in patients with stage IV recurrent, PD-L1–positive non-small-cell lung carcinoma (NSCLC), according to results reported recently at the European Society of Medical Oncology (ESMO) Congress 2016. 

Pearl Toh, 24 Nov 2016
New treatments such as pirfenidone and nintedanib slow lung function decline and progression of idiopathic pulmonary fibrosis (IPF), although response to treatment can vary dramatically among patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
16 Oct 2016
Irritable bowel syndrome and asthma share a bidirectional association, a new study reports. Further, atopy potentially plays a role in the underlying mechanisms of this association.
Audrey Abella, 09 May 2018
The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.